
CLAIMS

1. A pharmaceutical composition suitable for oral administration in which the composition comprises spray-dried particles of a compound of Formula I or a pharmaceutically acceptable salt thereof



[Formula I]

2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide

2. A pharmaceutical composition according to Claim 1 comprising spray-dried particles of a compound of Formula I.

3. A pharmaceutical composition according to Claim 1 or 2 in which the compound of Formula I is substantially amorphous.

4. A pharmaceutical composition according to Claim 1, 2 or 3 which further comprises one or more excipients, preferably in which the composition comprises the excipient hydroxypropyl methyl cellulose acetate succinate (HPMCAS).

5. A pharmaceutical composition according to Claim 4 in which the mass ratio of the compound of Formula I to excipient is from 1:100 to 1:1, preferably in which the mass ratio of the compound of Formula I to excipient is from 1:15 to 1:2.

6. A pharmaceutical composition according to any preceding claim in which:

(a) the particles are obtainable by spray-drying from a solution comprising an organic solvent selected from dichloromethane, methanol, and mixtures thereof; and/or

(b) the pharmaceutical composition further comprises one or more pharmaceutically acceptable binders and/or carriers and/or excipients and/or diluents and/or adjuvants.


7. A pharmaceutical composition according to any preceding claim in the form of a solid oral dosage form.

8. A pharmaceutical composition according to Claim 7 in the form of granules.

9. A pharmaceutical composition according to Claim 7 in the form of a tablet.

10. A pharmaceutical composition according to any preceding claim in the form of a liquid oral dosage form, preferably in which the liquid oral dosage form further comprises a pharmaceutically acceptable buffer having a pKa in the range 6.0 to 8.0, and more preferably in which the buffer is from 1 mM to 200 mM phosphate buffer and in which the composition is buffered to about pH 7.

11. A method of producing a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof



[Formula I]

2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide

in which the method comprises spray-drying a solution of the compound of Formula (I) or salt thereof.

12. A method according to Claim 11 comprising:

(i) dissolving one or more excipients in a solvent;

(ii) adding the compound of Formula I to the solution produced in step (i); and

(iii) spray drying the solution produced in step (ii).

13. A method according to Claim 12 in which:

the excipient is hydroxypropyl methyl cellulose acetate succinate (HPMCAS);


the solvent is a mixture of dichloromethane and methanol, in which the volume ratio of dichloromethane to methanol is from 5:1 to 1:1;

the concentration of the excipient in the solvent is from 5% to 20% w/v; and

the compound of Formula I is added to the solution of the excipient in the solvent to give a concentration of 0.5% to 10% by mass.

14. A pharmaceutical composition suitable for oral administration in which the composition comprises substantially amorphous particles of a compound of Formula I or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising spray-dried particles of a compound of Formula I or a pharmaceutically acceptable salt thereof



[Formula I]

2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide.

16. A pharmaceutical composition according to Claim 15 in which the pharmaceutical composition comprises spray-dried particles of a compound of Formula I.

17. A pharmaceutical composition according to Claim 15 or 16 in which:

(a) the compound of Formula I is substantially amorphous; and/or

(b) the pharmaceutical composition further comprises one or more excipients; and/or

(c) the particles are obtainable by spray-drying from a solution comprising ethanol.

18. A pharmaceutical composition according to Claim 15, 16 or 17 which is in the form of a solution, syrup, emulsion or suspension.

19. A pharmaceutical composition according to any of Claims 1 to 10 and 14 to 18 for use in a method of treatment of a human or animal subject in need thereof.

20. Use of a pharmaceutical composition according to any of Claims 1 to 10 and 14 to 18 in the manufacture of a medicament for use in the prevention or treatment of fungal infection in a human or animal subject in need thereof.